but the risk can be reduced close to 1% with adequate anticoagulation [2] . Elective cardioversion (ECV) for >48h AF increases the risk of stroke substantially and the reported rates of thromboembolic events after ECV have varied between 3-7% in non-anticoagulated patients [3, 4] . In spite of the increased post-cardioversion risk, the target INR (2.0-3.0) for ECV has been similar to the general anticoagulation recommendations in the long-term management of AF, and is based on consensus of observations made in observational studies investigating anticoagulation for stroke prevention in AF [5, 6] . Current guidelines recommend a minimum of 3 weeks of therapeutic anticoagulation prior to ECV and 4 weeks after the procedure with frequent INR controls for warfarin [5] . However, little is known how periprocedural INR levels predict thromboembolic events.
In this study, we sought to evaluate whether the intensity of periprocedural anticoagulation with vitamin K antagonists in adequately anticoagulated patients predicts thromboembolic events after ECV of AF in contemporary clinical practice. Our hypothesis was that a more intense periprocedural anticoagulation is associated with a lower incidence of thromboembolic events.
METHODS
The FinCV2 study ([http://] www.ClinicalTrials.gov, identifier NCT02850679) is part of an ongoing study program exploring thrombotic and bleeding complications of AF in Finland [7] [8] [9] [10] [11] .
ACCEPTED MANUSCRIPT
The current study is a prespecified report from FinCV2 study. 
Ethics
The study received approval of the Medical Ethics Committee of the Hospital District of Southwest Finland and the ethics committee of the National Institute for Health and
Welfare. The study conforms to the Declaration of Helsinki. Informed consent was not required due to the retrospective registry set-up of the study.
Statistics
The unpaired t-test or Mann-Whitney test was used to compare continuous variables and Carolina) were used to perform all analyses as appropriate.
RESULTS
After patients with inadequate preprocedural warfarin treatment or partially unavailable INR data as well as patients receiving direct oral anticoagulants or low molecular weight heparin at the time of ECV were excluded, the final study population comprised of 1021 patients and 1424 ECVs (Figure 1 ). 
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Outcomes
At 30-day follow-up after ECV, 4 (0.3%) strokes and 2 (0.1%) TIAs were detected (Table 1 ).
There were no systemic emboli, but one patient suffered a pulmonary embolism one day after a successful ECV. Additionally, one (0.1%) major bleed and one (0.1%) clinically relevant non-major bleed (1 traumatic subdural haemorrhage and 1 bleeding after dental procedure causing sinus perforation and requiring nasal tamponade) occurred during the follow-up. No spontaneous bleeds were detected. Two patients (0.1%) died during follow-up (1 associated with stroke and 1 with congestive heart failure, renal failure and infection). One death and one major bleed were detected in patients with INR 2.0-2.4 and INR≥2.5 at ECV, respectively.
Median time to a stroke/TIA was 4 (IQR 9.5) days after ECV. The median CHA 2 DS 2 -VASc-score was 2 (IQR 1.25) in patients suffering thromboembolic events. All thromboembolic events occurred after successful ECVs.
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Intensity of anticoagulation and risk of thromboembolism
The risk for a thromboembolic event was higher in the group of patients with low (2.0-2.4) therapeutic INR at ECV than in those with INR≥2.5 at ECV (5/529 (0.9%) vs. 1/895 (0.1%), p=0.03) (Figure 2 ). Baseline characteristics of these patient groups were similar, but patients without prior AF episodes had more often (p<0.05) low therapeutic INR values at ECV ( Table   2 .) The results did not change when only the first ECV of each patient was analysed ( 
DISCUSSION
In this large retrospective multi-center study patients with low (2.0-2.4) therapeutic INR at ECV or those with subtherapeutic (<2.0) INR measurements within 21 days after ECV had an increased risk for thromboembolic events (Figure 2) . Importantly, every fourth patient
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10 experienced a drop of INR to subtherapeutic level after ECV, and low periprocedural INR levels appeared to predict the drop in INR after ECV.
Modern oral anticoagulation has reduced AF-related stroke risk to 0.1-0.2%/month in the long-term treatment [2] . The risk of thromboembolic complications after ECV performed during therapeutic oral anticoagulation has ranged from 0.3% to 0.9% in previous trials [13] [14] [15] . This means that patients undergoing ECV are exposed to a 1.5-4.5 -fold higher risk for stroke during the post-cardioversion month compared to patients without a cardioversion and there is a clinical need to reduce ECV related strokes. The magnitude of the problem is illustrated by a recent finding that 6.4% of all strokes associated with paroxysmal or persistent AF are preceded by a cardioversion [10] . In line with this reasoning, inadequate pericardioversion anticoagulation may have contributed to the poor outcome in the rhythm control arm of the AFFIRM study [16] .
Thrombus formation in the left atrial appendage is responsible for the majority of thromboembolic events after cardioversion. In spite of the solid theoretical background, several clinical trials have concluded that performing transoesophageal echocardiography to exclude thrombus formation prior to ECV does not reduce the rate of stroke compared to conventional anticoagulation regime [13, 15] . Early cardioversion may, however, be advantageous in this respect, since the risk for stroke has shown to be low (0.1% per month) in patients undergoing cardioversion within 48 hours after the onset of AF during long-term oral anticoagulation [11] . This finding is probably explained by less atrial stunning and thrombus formation after the conversion of shorter episode of AF to sinus rhythm.
One important finding of our study was the high incidence of subtherapeutic INR values during the most vulnerable period of atrial stunning after the cardioversion. This finding may
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11 reflect the more floppy general attitude on anticoagulation after achieving the sinus rhythm and therefore assuming a lower risk of thromboembolism. The use of non-Vitamin K antagonist oral anticoagulants (NOACs) should help to ensure stable therapeutic periprocedural anticoagulation in patients with good drug compliance. The conventional dosing of NOACs has, however, provided no significant advantage over vitamin K antagonist anticoagulants in this setting, although numerically the event rates have been slightly lower and less delays to cardioversion have been reported [14, 15, 17 ].
The target pericardioversion anticoagulation level is based on consensus opinion and does not differ from the general anticoagulation recommendations in the long-term management of AF in spite of the higher temporary risk of thromboembolic complications after successful cardioversion. Our findings support the view that the higher intensity of periprocedural anticoagulation -even within the current therapeutic range -may reduce the risk of thromboembolic complications. These observations are in line with an earlier study where no embolic events were detected after 779 ECVs with periprocedural INR ≥ 2.5 whereas 7 (0.9%) embolic events occurred after 754 ECVs with INR <2.5 [18] . Similarly, the risk of thromboembolism was numerically lower (0.3% vs 0.8%) during chronic anticoagulation with high dabigatran dose (150mg twice daily) than with the lower dose (110mg twice daily) [19] .
In the light of present and earlier findings it seems unlikely that a short period of more intensive anticoagulation causes redundant rise in the risk for bleeds during the peri-and post-cardioversion treatment [6] , since the monthly rates for bleeds have been similar (0.1-0.3% per month) in trials investigating anticoagulation of non-valvular AF [2] and venous thromboembolism with higher doses of NOACs [20, 21] . Nevertheless, the efficacy and safety of the more intensive periprocedural anticoagulation of ECV in AF needs to be assessed in a prospective randomized trial.
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This study has all the limitations of a retrospective study. The total number of embolic events is low for definite conclusions and an interruption of anticoagulation treatment occurred in two patients with thromboembolic events. Furthermore, comprehensive periprocedural INR data was unavailable in all patients reducing the sample size. Events were not independently adjudicated, however, all events were diagnosed by the treating neurologist with appropriate imaging or systemic embolus confirmed by the attending vascular surgeon and by imaging. Moreover, all patients were from the catchment area of the participating hospitals and thus all thromboembolic events are treated in the same hospital. Despite the limitations, we feel that this data can guide future research and treatment decisions in patients undergoing ECV.
CONCLUSIONS
Our results provide indirect evidence that the increased risk of thromboembolic events related to ECV might be reduced by more aggressive anticoagulation and careful follow-up during the periprocedural period. However, further research is needed to definitely assess the efficacy and safety outcomes of the hypothesis. Our study demonstrates the importance of rigorous and good quality INR control after a successful ECV in stroke prevention. 
ECV= elective cardioversion; CHA 2 DS 2 -VASc = congestive heart failure, hypertension, age ≥ 75 years (doubled), diabetes mellitus, prior stroke, transient ischaemic attack or thromboembolism (doubled), vascular disease, age 65 to 74 years and sex category (female, unless <65 years and no other risk factors); TEE = transoesophageal echocardiography; INR = international normalized ratio; Pt = patient; M = male; F = female; TIA = transient ischaemic attack 
